Phage Therapy Market Size, Share, and Growth Analysis, By Product (Escherichia coli, Staphylococcus aureus), By Type (DsDNA Bacteriophage, SsDNA Bacteriophage), By Disease Indication, By End User, By Region - Industry Forecast 2025-2032

Global Phage Therapy Market size was valued at USD 29.8 million in 2023 and is poised to grow from USD 34.99 million in 2024 to USD 126.25 million by 2032, growing at a CAGR of 17.4% during the forecast period (2025-2032).

The global Phage Therapy Market is rapidly gaining traction in response to the escalating threat of antibiotic resistance, a pressing public health issue. Growth drivers include the rise of multidrug-resistant infections, increased investments in alternative antimicrobial therapies, and enhanced R&D efforts from both public and private sectors. Phage therapy offers high specificity against pathogens, maintains the normal microbiome, and has minimal side effects, making it an attractive treatment option. Government initiatives, particularly in North America and Europe, further stimulate innovation. However, regulatory uncertainties, limited clinical evidence, and logistical challenges hinder widespread adoption. Yet, advancements in genome sequencing and personalized medicine may overcome these barriers, signaling a promising future for phage therapy in combating superbugs and reshaping anti-infective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Phage Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Phage Therapy Market Segments Analysis

Global Phage Therapy Market is segmented by Product, Type, Disease Indication, End User and region. Based on Product, the market is segmented into Escherichia coli, Staphylococcus aureus, Salmonella, Pseudomonas aeruginosa and Others. Based on Type, the market is segmented into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage and Others. Based on Disease Indication, the market is segmented into Urinary Tract Infections, Chronic Otitis, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis and Other Disease Indications. Based on End User, the market is segmented into Hospital & Clinics, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Phage Therapy Market

The global phage therapy market is primarily driven by the rising threat of antimicrobial resistance (AMR), which occurs when bacteria evolve to resist antibiotics, complicating the treatment of infections. The misuse and overprescription of these medications have led to a significant rise in AMR cases, resulting in increased mortality rates, the spread of diseases, and escalating healthcare expenses. The World Health Organization projects that by 2050, AMR could cause up to 10 million deaths annually. As such, there is a growing need for alternative treatments like phage therapy to address these challenges and manage the increasing prevalence of chronic infections.

Restraints in the Global Phage Therapy Market

One of the primary obstacles facing the global phage therapy market is the insufficient clinical evidence supporting its efficacy and safety. Currently, most available research is limited to small-scale studies or compassionate use cases, which often lack the rigorous testing found in large randomized controlled trials. This deficiency undermines the confidence of healthcare professionals and regulatory bodies in phage treatments. Consequently, this skepticism hampers efforts to gain regulatory approval, establish acceptance among practitioners, and scale the therapy for broader use. As a result, the commercial introduction of phage therapy and its integration into standard treatment protocols are significantly hindered.

Market Trends of the Global Phage Therapy Market

The Global Phage Therapy market is witnessing a significant trend towards the integration of artificial intelligence and bioinformatics, revolutionizing treatment specificity and efficacy. As developers increasingly utilize AI-assisted phage-host prediction programs and automated screening platforms, the acceleration of phage selection and development is becoming more efficient and cost-effective. This technological innovation not only reduces development timelines but also enhances therapeutic precision, making phage therapy a promising component of personalized medicine. As a result, the market is poised for substantial growth, reflecting the rising demand for targeted treatments in the face of antibiotic resistance and complex infectious diseases.